|Back to main|
Data on Novo Nordisk's VIctoza - Analyst Blog
3/20/2013 1:49:00 PM
) recently announced results on Victoza (liraglutide) from a
phase IIIa study. The double-blind phase IIIa study was conducted
to evaluate the potential of Victoza to induce and maintain
weight loss in people afflicted with type II diabetes.
Novo Nordisk currently carries a Zacks Rank #2 (Buy).
Currently, companies like
Lannett Company, Inc.
WuXi Pharma Tech (Cayman) Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
LANNETT INC (LCI): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
WUXI PHARMATECH (WX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research